SecBot SecBot
Biotech Drug Report Generated Aug 27, 2026

rituximab

RDY·DR REDDYS LABORATORIES LTD
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and launched in the US (FDA approval ~August 2026). Now in commercial phase, with Fresenius Kabi handling US commercialization.
Why 4/10
Rituximab biosimilar was already approved by the FDA in early August 2026 (approximately 3.5 weeks ago). There is no upcoming binary regulatory catalyst for this specific drug within the next ~12 months. Dr. Reddy's is a large diversified pharma company (~$10.3B market cap) with many products, so this single biosimilar is not a binary value driver.
Actionable Insight NEUTRAL

The FDA approval is already priced in and was announced approximately 3.5 weeks ago. Watch for initial sales data from Fresenius Kabi's US commercialization and Dr. Reddy's quarterly earnings for any biosimilar revenue disclosures. For a diversified pharma company of RDY's size ($10.3B market cap), this single biosimilar is unlikely to be a major share-price mover. The more relevant catalysts would be broader pipeline updates, resolution of the Form 483 at Bachupally, and overall generics/biosimilars segment performance.

Price Chart

Loading chart...

Executive Summary

Rituximab (branded as Rituxan/MabThera) is a blockbuster anti-CD20 monoclonal antibody used to treat B-cell malignancies and autoimmune diseases. Dr. Reddy's Laboratories (NYSE: RDY) developed a biosimilar version (code DRL_RI) that received U.S. FDA approval in early August 2026. Fresenius Kabi will exclusively commercialize it in the U.S. The drug is already approved and entering a competitive market where at least three other rituximab biosimilars (Truxima, Ruxience, Riabni) are already established. For a large, diversified pharma company like Dr. Reddy's, this is a positive addition to its biosimilars portfolio but not a company-defining event.

How It Works

Rituximab is a monoclonal antibody that targets the CD20 protein on the surface of B-cells (a type of white blood cell). It marks those cells for destruction by the immune system. It is used to treat B-cell cancers like non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as autoimmune diseases like rheumatoid arthritis. Dr. Reddy's developed a biosimilar version, a nearly identical copy of the original biologic drug Rituxan (Roche/Genentech).

Trial Status

Dr. Reddy's completed the full set of clinical studies for its rituximab biosimilar candidate (DRL_RI) in January 2023. The U.S. FDA accepted the BLA for substantive review in July 2023. The FDA approved the biosimilar on or around August 1, 2026. Fresenius Kabi will exclusively commercialize the product in the U.S. market. Dr. Reddy's already markets rituximab in Europe, India, and other emerging markets.

The Two-Sided Case

▲ Bull Case4
FDA approval validates Dr. Reddy's capabilities in developing and manufacturing complex biologic medicines for regulated markets, enhancing its credibility.
Fresenius Kabi's established US oncology/immunology sales infrastructure should enable meaningful market penetration.
Dr. Reddy's already has a commercial presence for rituximab in Europe, India, and emerging markets, providing international revenue streams.
The US biosimilar market for rituximab is sizable, the reference product Rituxan has been a multi-billion dollar drug, and additional biosimilar competition can drive volume growth.
▼ Bear Case5
At least three rituximab biosimilars (Truxima, Ruxience, Riabni) were already approved in the US before Dr. Reddy's entry, creating a crowded market with pricing pressure.
Dr. Reddy's does not directly commercialize in the US, Fresenius Kabi handles US sales, so Dr. Reddy's captures only the manufacturing/supply margin rather than full commercial value.
Dr. Reddy's is a large, diversified pharma company where this single biosimilar represents a modest revenue contributor, not a material growth driver.
The analyst consensus on RDY is mixed (only 14 buy/strong buy vs 19 sell/strong sell out of 45 ratings), suggesting limited enthusiasm about near-term catalysts including this launch.
Recent FDA Form 483 observations at a Dr. Reddy's Hyderabad facility introduce regulatory compliance risk that could affect broader operations.

Upcoming Catalysts

  • Commercial launch dynamics and initial sales data from Fresenius Kabi
  • Potential future market share reports in the US rituximab biosimilar market
  • Quarterly earnings updates from Dr. Reddy's referencing biosimilar revenue contribution

Source Filing

The SecBot filing or press-release report that triggered this drug report:

DR REDDYS LABORATORIES LTD 6-K RDY ·Originating report

Sources · 7

Hover a chip for the title
1 fresenius-kabi.com2 fresenius-kabi.com3 pharma.economictimes.indiatimes.com4 business-standard.com5 pharmatutor.org6 sec.gov7 sec.gov